Last reviewed · How we verify
NCT05962294
Real World Study of Oxycodone Sustained-release Tablets for Patients With Moderate to Severe Cancer Pain
trial in Cancer Pain in 916 participants. Status unknown.
31 May 2024
Quick facts
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 916 |
| Start date | 1 June 2023 |
| Primary completion | 31 May 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 1 location across China |
Conditions studied
- Cancer Pain — all drugs for Cancer Pain →
- Real-world Study — all drugs for Real-world Study →
- Oxycodone — all drugs for Oxycodone →
Sponsor
Henan Cancer Hospital
Who can join
18 and older, any sex, with Cancer Pain or Real-world Study. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this real world study is to observe the efficacy and safety of Oxycodone Hydrochloride Sustained-release Tablets in the treatment of moderate to severe cancer pain participants in real clinical practice. After entering the study, participants will take Oxycodone Hydrochloride Sustained-release Tablets. The investigators need to observe and record relevant data, and finally analyze and summarize the data to understand the efficacy and safety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05962294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer Pain
Currently open trials in the same condition.
- NCT07445386 — Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain · NA · recruiting
- NCT07405645 — Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy · NA · recruiting
- NCT07382297 — Effect of Adding Ultrasound Guided IPACK Block to Adductor Canal Block for Postoperative Pain in Knee Tumor Excision · NA · recruiting
- NCT07318519 — Cognitive Behavioral Theory-assisted Virtual Reality for Chronic CANcer Pain (VR-CAN) · NA · recruiting
- NCT06489769 — Opioid Misuse in Patients with Cancer · recruiting
Other Henan Cancer Hospital trials
Trials by the same sponsor.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
- NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
- NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
- NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05962294 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
- Last refreshed: 27 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05962294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing